CSL Shares Make A Huge Intraday Swing – What Happened?

CSL Limited shares (ASX: CSL) experienced extreme volatility today, crashing to a multi-year low before recovering significantly as markets digested the dual shock of an abrupt CEO departure and disappointing half-year results.

The CSL share price opened sharply lower, plummeting to A$150.21 almost right out of the gate, making a new multi-year low, before staging a recovery to close at A$163.44, down 4.64% on the day. The intraday swing of more than 8% from trough to close reflected intense uncertainty as markets grappled with leadership instability and deteriorating financial performance at Australia’s second-largest listed company.

The dramatic sell-off was triggered by two simultaneous announcements that caught markets off guard. CSL revealed that Dr Paul McKenzie would retire immediately as chief executive after three years in the role, with former senior executive Gordon Naylor appointed as interim CEO. The timing proved particularly unfortunate, coinciding with the release of half-year results that showed underlying net profit after tax and amortisation (NPATA) declining 7% to US$1.9 billion.

The reported NPAT figure painted an even bleaker picture, plunging 81% to US$401 million due to approximately US$1.1 billion in one-off restructuring costs and impairments. Revenue across the group fell 4% to US$8.3 billion, with weakness concentrated in CSL’s flagship immunoglobulin business.

CSL Behring, the company’s largest division, reported a 7% revenue decline to US$5.5 billion. Immunoglobulin sales fell 6%, partly attributed to Medicare Part D reforms in the United States that altered reimbursement dynamics for plasma-derived therapies. The policy changes have created headwinds that management had previously flagged but which appear to be materialising more severely than anticipated.

The CSL Seqirus influenza vaccine business posted a 2% revenue decline to US$1.6 billion, though this largely reflected the absence of non-recurring avian influenza outbreak revenue that boosted the prior corresponding period. CSL Vifor provided the sole bright spot, with revenue rising 12% to US$1.2 billion on strong nephrology product growth, though generic competition continued to erode iron deficiency therapy sales.

Chairman Dr Brian McNamee stated that the board and Dr McKenzie agreed it was the right time for new leadership to drive CSL’s strategic transformation and performance, though the immediate nature of the departure raised questions about whether the decision was entirely mutual or reflected board dissatisfaction with recent results.

Despite the profit decline, CSL reaffirmed its full-year guidance and announced an expansion of its share buyback program to US$750 million, signalling management confidence in the underlying business trajectory. The company pointed to expected second-half improvements driven by seasonal vaccine demand and the annualization of cost restructuring initiatives.

Markets have shown little patience with CSL’s performance under Dr McKenzie’s leadership, with shares now down 36% over the past year and 41% over five years. The five year chart above makes painful viewing for long term holders of CSL. The decline has been particularly pronounced relative to the broader ASX 200, reflecting concerns about competitive pressures in core markets, regulatory headwinds, and execution challenges in integrating the Vifor acquisition.

CSL’s reaffirmed guidance and expanded buyback suggest management sees the current weakness as temporary rather than structural, banking on second-half recovery and long-term demographic tailwinds in plasma therapies. However, markets will demand concrete evidence of stabilisation before rewarding the shares with a sustained recovery, particularly given the leadership vacuum and mounting competitive pressures that have defined the current era.